➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
McKesson
Mallinckrodt
Merck

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

ASPIRIN AND DIPYRIDAMOLE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Aspirin And Dipyridamole, and what generic alternatives are available?

Aspirin And Dipyridamole is a drug marketed by Amneal Pharms, Ani Pharms, Barr, Dr Reddys, Glenmark Pharms Sa, Lannett Co Inc, Micro Labs, Par Pharm Inc, Sandoz Inc, Sun Pharm, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in ASPIRIN AND DIPYRIDAMOLE is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aspirin And Dipyridamole

A generic version of ASPIRIN AND DIPYRIDAMOLE was approved as aspirin; dipyridamole by BARR on August 14th, 2009.

  Try it Free

Summary for ASPIRIN AND DIPYRIDAMOLE
US Patents:0
Applicants:11
NDAs:11
Finished Product Suppliers / Packagers: 13
Clinical Trials: 25
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in ASPIRIN AND DIPYRIDAMOLE?ASPIRIN AND DIPYRIDAMOLE excipients list
DailyMed Link:ASPIRIN AND DIPYRIDAMOLE at DailyMed
Drug patent expirations by year for ASPIRIN AND DIPYRIDAMOLE
Recent Clinical Trials for ASPIRIN AND DIPYRIDAMOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rutgers, The State University of New JerseyPhase 3
RĂ©gion Hauts de France, FrancePhase 3
University Hospital, LillePhase 3

See all ASPIRIN AND DIPYRIDAMOLE clinical trials

US Patents and Regulatory Information for ASPIRIN AND DIPYRIDAMOLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 206392-001 Mar 8, 2016 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Micro Labs ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 209929-001 Aug 11, 2021 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Dr Reddys ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 209048-001 Oct 10, 2018 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Par Pharm Inc ASPIRIN AND DIPYRIDAMOLE aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 207944-001 Jan 18, 2017 AB RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Express Scripts
McKesson
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.